Genprex (GNPX), Cancer, Diabetes and Gene Therapy Genprex is now part of the Russell 3000

Genprex (GNPX), Cancer, Diabetes and Gene Therapy Genprex is now part of the Russell 3000

Good day everyone,

We are initiating coverage of Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company involved in developing various approaches to treating cancer, currently focused on non-small cell lung cancer, and autoimmune therapy currently focused on diabetes. GNPX has a proprietary technology platform designed to deliver tumor suppressor genes to cancer cells.

Current price $3.09 per share
Outstanding shares (est.) 38.63M
Shares in Float (est.) 26.78M
Insider ownership 23%
Institutional ownership 12.82%

We have reported on GNPX shares a few times this year, in January, in early May and again in June. Both times GNPX shares have realized near term gains as the shares went from our initial alert price of $1.20 per share to a high of $7.03 in February. After consolidating to $1.89 in March, the company shares have steadily climbed to today’s level.

The company was added to the Russell 3000 Index on Friday, June 26, 2020.

Potential near term to mid-term share catalysts:

Any updates on the company’s Phase I/II clinical trial with GPX-001 being combined with AstraZeneca’s Tagrisso.

Any updates on a Phase I/II clinical trial of a Phase I/II clinical trial of GPX-001 combined with Merck’s Keytruda.

The advancement of GPX-002 for diabetes from pre-clinical to Phase I clinical trial.

Date Brokerage Action Rating Price Target
5/26/2020 Noble Financial Reiterated Rating Buy $5.00
4/22/2020 Alliance Global Initiated Coverage Buy

Genprex is a development stage gene therapy company with a market cap of $119M. Pluristem (PSTI) is a development stage gene therapy company with a market cap of $240M. We believe GNPX has better potential than PTSI yet only has half the market cap.

The GNPX pipeline and collaborations:

The company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC), uses the company’s unique, proprietary Oncoprex™ nanoparticle delivery platform which delivers cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanoparticles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The active ingredient in our lead product candidate, GPX-001, is the TUSC2 gene, a tumor suppressor gene.

AstraZeneca’s Tagrisso had more than $3 billion in worldwide gross sales in 2019, and Tagrisso is AstraZeneca’s highest grossing product. Given Genprex’s Fast Track Designation and Tagrisso’s status as the current standard of care in EGFR-mutated NSCLC. In January 2020, GNPX received a United States FDA Fast Track Designation for use of GPX-001 in combination with Tagrisso® for the treatment of NSCLC.

Merck’s Keytruda generated $11.1 billion in worldwide sales in 2019, and Keytruda is Merck’s highest grossing product. Keytruda is the standard of care in non-EGFR mutated NSCLC. Genprex plans to initiate a Phase I clinical trial evaluating GPX-001 in combination with Keytruda.

GPX-002 is a gene therapy for diabetes, is the most recent addition of their licensed technologies. GPX-002 was developed by researchers at the University of Pittsburgh and is exclusively licensed to GNPX. GPX-002 is the only gene therapy candidate that has the potential to cure Type 1 and Type 2 diabetes

Oconoprex Nanoparticle Delivery System is a platform has been designed and optimized to deliver cancer-fighting genes into the patient’s body. These cancer-fighting genes are encapsulated in nanoscale hollow spheres called “nanoparticles,” which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The Oconoprex delivery system may be a candidate vehicle for delivering a variety of drugs.

Genprex is bringing its state-of-the-art gene therapy to some of the largest markets in biopharma, lung cancer and diabetes. What makes the GNPX approach different is the nanoparticle delivery system for its genes.

It seems GNPX shares are hovering in value range. They are trading 56% off their 52-week high and the market cap is half that of their closest competitor in scope. The shares currently lead their 50 DMA and 200 DMA of $3.08 and $1.92, respectively.

Updated report coming soon,

The Team


Privacy Policy and Disclaimer

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties?

We hate spam and we do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.

What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form. This includes your email address only.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address

What do we use your information for?

When we collect your email it is used for one purpose to send you the free information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.

We send periodic emails

The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.

How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use a secure third party to send email to you.

Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.

Online Privacy Policy Only

This online privacy policy applies only to information collected through our website, social media and press releases and not to information collected offline.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may reply to this email.


This website/newsletter is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. SCS LLC has been compensated sixteen thousand five hundred dollars by venado media llc for this weeks coverage of gnpx. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.